Related Experiment Videos
Stimulation of plasma fibronectin production in mice by muroctasin
1Department of Microbiology and Immunology, School of Health Sciences, Kyorin University, Tokyo, Japan.
Abstract:
The production of plasma fibronectin (PFN) in mice treated subcutaneously with N2-[(N-acetylmuramoyl)-L-alanyl-D-isoglutaminyl]-N6-stearoyl-L-lysine (MDP-Lys(L18), muroctasin), was examined. The plasma levels of PFN in mice increased significantly by treatment with a single dose of 10 to 100 micrograms/mouse of MDP-Lys(L18). A slight strain difference in the PFN levels among Std: ddY, C3H/He, and DBA 2 mice was observed: the percent increases at the maximal level in Std: ddY, C3H/He, and DBA/2 mice were 21.6, 19.9, and 10.4, respectively. In Std: ddY mice, the concentration of PFN reached the maximal level at 15 h post-treatment, and decreased gradually of the normal level by 48 h. These results indicate that MDP-Lys(L18) stimulates the PFN production in mice.
Insights
Muroctasin (MDP-Lys(L18)) significantly boosts plasma fibronectin (PFN) levels in mice. This immune-stimulating compound shows dose-dependent effects and varied responses across different mouse strains.
Area of Science:
- Immunology
- Pharmacology
- Biochemistry
Background:
- Plasma fibronectin (PFN) is a glycoprotein involved in various biological processes, including immune response and tissue repair.
- Understanding factors that modulate PFN levels is crucial for developing therapeutic strategies.
- N2-[(N-acetylmuramoyl)-L-alanyl-D-isoglutaminyl]-N6-stearoyl-L-lysine (MDP-Lys(L18), also known as muroctasin) is a synthetic immunomodulator.
Purpose of the Study:
- To investigate the effect of muroctasin (MDP-Lys(L18)) on plasma fibronectin (PFN) production in mice.
- To determine the dose-dependency and temporal profile of PFN induction by MDP-Lys(L18).
- To examine potential strain-specific differences in the PFN response to MDP-Lys(L18).
Main Methods:
- Subcutaneous administration of varying doses (10-100 micrograms/mouse) of MDP-Lys(L18) to different mouse strains (Std: ddY, C3H/He, DBA/2).
- Measurement of plasma fibronectin (PFN) levels at different time points post-treatment.
- Comparative analysis of PFN levels across different mouse strains and dose groups.
Main Results:
- A single subcutaneous dose of MDP-Lys(L18) significantly increased plasma fibronectin (PFN) levels in mice in a dose-dependent manner.
- Maximal PFN increases observed were 21.6% in Std: ddY, 19.9% in C3H/He, and 10.4% in DBA/2 mice.
- In Std: ddY mice, PFN levels peaked at 15 hours post-treatment and returned to baseline by 48 hours.
Conclusions:
- MDP-Lys(L18) (muroctasin) effectively stimulates the production of plasma fibronectin (PFN) in mice.
- The PFN response to MDP-Lys(L18) exhibits variations among different mouse strains.
- MDP-Lys(L18) demonstrates potential as an agent for modulating PFN levels.